-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On January 6, 2022, Novartis announced a partnership with Alnylam to use Alnylam's proprietary small interfering ribonucleic acid (siRNA) technology to develop a target for a target identified by Novartis.
An innovative therapy to restore functional hepatocyte regeneration in patients with end-stage liver disease (ESLD), providing an alternative to liver transplantation for patients with liver failure
.
End-stage liver disease is a progressive disease, usually caused by cirrhosis, characterized by the destruction of healthy liver tissue and the loss of vital liver functions
.
The disease kills more than 1 million people worldwide each year
.
Currently, liver transplantation is the only treatment for end-stage liver disease, yet the number of transplanted organs is limited
.
There is therefore an urgent need for pharmacological alternatives to liver transplantation to regenerate liver tissue and thereby restore the essential metabolic and synthetic processes managed by the liver
.
RNA interference (RNAi), a natural cellular process that effectively silences or inhibits gene expression, was awarded the 2006 Nobel Prize in Physiology or Medicine for its discovery
.
Alnylam is a star company in the field of RNAi therapy development, with 4 of the company's RNAi therapies developed alone or in combination with regulatory approvals
.
Under the terms of the collaboration, during an exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs against specific targets developed by Novartis
.
Once a lead candidate is identified, Novartis will conduct further development and clinical studies
.
"There is still a huge unmet need for novel drugs to treat end-stage liver disease ," said James Bradner, Ph.
D.
, president of the Novartis Institutes for Biomedical Research.
"Based on research in regenerative medicine, we have devised a repair strategy that may provide potential for liver failure
.
Patients provide transformative benefits
.
We are now excited to partner with Alnylam as its proprietary siRNA platform is most instrumental in advancing this concept to clinical research
.
” Reference: [1] Novartis Announces Collaboration With Alnylam To Explore Targeted Therapy To Restore Liver Function.
Retrieved January 6, 2022, from https:// Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
An innovative therapy to restore functional hepatocyte regeneration in patients with end-stage liver disease (ESLD), providing an alternative to liver transplantation for patients with liver failure
.
End-stage liver disease is a progressive disease, usually caused by cirrhosis, characterized by the destruction of healthy liver tissue and the loss of vital liver functions
.
The disease kills more than 1 million people worldwide each year
.
Currently, liver transplantation is the only treatment for end-stage liver disease, yet the number of transplanted organs is limited
.
There is therefore an urgent need for pharmacological alternatives to liver transplantation to regenerate liver tissue and thereby restore the essential metabolic and synthetic processes managed by the liver
.
RNA interference (RNAi), a natural cellular process that effectively silences or inhibits gene expression, was awarded the 2006 Nobel Prize in Physiology or Medicine for its discovery
.
Alnylam is a star company in the field of RNAi therapy development, with 4 of the company's RNAi therapies developed alone or in combination with regulatory approvals
.
Under the terms of the collaboration, during an exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs against specific targets developed by Novartis
.
Once a lead candidate is identified, Novartis will conduct further development and clinical studies
.
"There is still a huge unmet need for novel drugs to treat end-stage liver disease ," said James Bradner, Ph.
D.
, president of the Novartis Institutes for Biomedical Research.
"Based on research in regenerative medicine, we have devised a repair strategy that may provide potential for liver failure
.
Patients provide transformative benefits
.
We are now excited to partner with Alnylam as its proprietary siRNA platform is most instrumental in advancing this concept to clinical research
.
” Reference: [1] Novartis Announces Collaboration With Alnylam To Explore Targeted Therapy To Restore Liver Function.
Retrieved January 6, 2022, from https:// Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
